Travera, Genetic Alliance Partner to Validate Functional Test for Predicting Cancer Treatment Efficacy
The test measures a patient's tumor cell weight after exposure to a drug to gauge whether they are likely to benefit from it.
Oxford BioTherapeutics, Boehringer Ingelheim Extend Drug Discovery Collaboration
The firms have previously advanced two programs identified by Oxford's platform into Phase I clinical development.
BostonGene, University of Miami Ink Precision Oncology Collaboration in High-Grade B-Cell Lymphoma
BostonGene will use its next-generation sequencing technologies to analyze tumor samples collected at Sylvester and help guide treatment selection accordingly.
ObjectiveHealth, Urology of St. Louis Launch Research Partnership
A joint clinical research center based in St. Louis will provide access to investigative therapies and diagnostic tools to improve outcomes in urologic diseases.
Ideaya Biosciences, Amgen Starting Phase I/II Trial of Targeted Treatment Combo in MTAP-Null Tumors
The US Food and Drug Administration cleared the firms' investigational new drug application to evaluate IDE397 plus AMG193 in an Amgen-sponsored trial.